Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
Ortin Global Ltd (ORTINGLOBE) is currently trading at 17.82 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ortin Laboratories Limited is a leading pharmaceutical manufacturer in India, specializing in a wide range of pharma formulations including tablets, capsules, syrups, and ointments. The company has strategically expanded its manufacturing capabilities and geographical reach by obtaining certifications for exports to Asian, African, and Middle East countries. Ortin Laboratories expanded its business scope through the amalgamation with Vineet Laboratories, enhancing its portfolio with fine chemicals and bulk drug intermediates. The company's manufacturing facilities adhere to WHO GMP Standards, marking a commitment to quality and international compliance. Ortin Laboratories has consistently upgraded and expanded its facilities, indicating a focus on scaling production and meeting global standards.
Over the past 52 weeks, Ortin Global Ltd has traded between a low of ₹9.57 and a high of ₹19.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ortin Global Ltd has a market capitalization of approximately 13.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ortin Global Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -15.47 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 13.86 Cr, Ortin Global Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ortin Global Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ortin Global Ltd is -15.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
1
Neutral
6
Bullish
7
Bearish
1
Neutral
6
Bullish
39
Bearish
0
Neutral
0
Bullish
32
Ortin Laboratories Limited is a leading pharmaceutical manufacturer in India, specializing in a wide range of pharma formulations including tablets, capsules, syrups, and ointments.
The company has strategically expanded its manufacturing capabilities and geographical reach by obtaining certifications for exports to Asian, African, and Middle East countries.
Ortin Laboratories expanded its business scope through the amalgamation with Vineet Laboratories, enhancing its portfolio with fine chemicals and bulk drug intermediates.
The company's manufacturing facilities adhere to WHO GMP Standards, marking a commitment to quality and international compliance.
Ortin Laboratories has consistently upgraded and expanded its facilities, indicating a focus on scaling production and meeting global standards.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
14 Cr
Low Risk
-15.5
27.5
—
10.7
19.15
9.57
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
34.06 | 21 Cr | 40.55 | 2.09 | 0.00 | 7.06 | 7.06 | 2.60 | |
44.00 | 19 Cr | 9.44 | 1.16 | 0.00 | 10.58 | 11.64 | 3.48 | |
14.01 | 14 Cr | -25.02 | 0.00 | 0.00 | 9.68 | -17.74 | -4.15 | |
17.17 | 14 Cr | -15.47 | 10.66 | 0.00 | -73.01 | -42.20 | -23.24 | |
18.73 | 9 Cr | 624.33 | 1.00 | 0.00 | 2.47 | 7.06 | 0.06 | |
1.98 | 8 Cr | -49.50 | 1.72 | 0.00 | -6.62 | -0.04 | -0.30 | |
7.61 | 8 Cr | 54.36 | 9.07 | 0.00 | 2.56 | 0.67 | 4.00 |
